Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples